Epigenetic CKM Target orphan genetic diseases with precision epigenetic gene modulation using CRISPR-GNDM platform. Position Modalis as a specialized partner for rare disease programs seeking locus-specific gene expression modulation without DNA cleavage.

Strategic Partnerships Leverage recent collaborations and seek co-development or funding opportunities with biopharma and contract research organizations, as evidenced by ties to Ginkgo Bioworks and CNS gene therapy initiatives, to expand pipeline and de-risk development through shared resources.

FSHD Focus Prioritize opportunities in facioscapulohumeral muscular dystrophy and related neuromuscular indications, aligning messaging with Solve FSHD and XPRIZE Healthspan recognition to attract grant funding, clinical partnerships, and joint research ventures.

Global R&D Footprint Highlight Tokyo HQ with Cambridge R&D presence to appeal to multinational sponsors seeking cross-border innovation, translational capabilities, and access to diverse patient populations for rare disease trials.

Financial Signals Acknowledge the current revenue range and recent funding level while noting a minor U.S. subsidiary loss event; frame conversations around scalability, risk mitigation, and investor-friendly milestones to attract strategic investment and collaboration opportunities.